Ingenuity Systems to Integrate Spotfire Analytics
News Apr 05, 2006
Spotfire and Ingenuity Systems have announced a collaboration to establish integration between Spotfire's DecisionSite® and Ingenuity Pathways Analysis which enables a streamlined workflow between applications to ultimately help mutual customers expedite decision-making in drug discovery research.
"Our customers have made significant investments in data centric information technology. However, they lack the analytical tools that can be broadly deployed among researchers to quickly reveal comprehensive and actionable information," said Tuan Nguyen, VP, Partner and Professional Services of Ingenuity Systems.
"Integrating with Spotfire analytics gives researchers the premium experience for interacting with data to achieve a marketplace advantage."
The integration between Ingenuity Pathway Analysis and Spotfire enables researchers to become organizational difference-makers. Difference-makers uncover hidden insights; sift through scenarios, and to respond to new market events by translating quantitative information to business response. Through the integration, researchers can combine experimental and biological data for faster drug discovery.
"Life sciences companies are finding that their existing IT investments do not facilitate rapid insights or response to data," said Christian Marcazzo, Senior Director of Life Sciences marketing at Spotfire. "By integrating with Ingenuity Pathways Analysis, researchers can now interact with data in an intuitive fashion, allowing them to quickly arrive at decisions and take action earlier."
Herpesvirus and Alzheimer's Link: High abundance of Herpes genes in postmortem Alzheimer's brain tissueNews
Data from three different brain banks to suggest that human herpesviruses are more abundant in the brains of Alzheimer's patients and may play a role in regulatory genetic networks that are believed to lead to the disease.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Gene-edited Pigs are Resistant to Billion-dollar VirusNews
Scientists have produced pigs that can resist one of the world’s most costly animal diseases, by changing their genetic code. Tests with the virus – called Porcine Reproductive and Respiratory Syndrome, or PRRS – found the pigs do not become infected at all. The animals show no signs that the change in their DNA has had any other impact on their health or wellbeing.READ MORE